Status:
COMPLETED
Evaluation of Humira Retention Rate in Psoriasis Patients in Daily Practice and Assessment of Work Productivity and Quality of Life
Lead Sponsor:
AbbVie (prior sponsor, Abbott)
Collaborating Sponsors:
Veeda Clinical Research
Conditions:
Psoriasis
Eligibility:
All Genders
18-99 years
Brief Summary
This observational study will document to what extent in daily clinical practice Humira (adalimumab) therapy is continued, interrupted or permanently discontinued during a follow-up period of 2 years....
Eligibility Criteria
Inclusion
- Patients \> or = 18 years
- Patient with chronic plaque psoriasis
- Patient newly initiated on Humira
- Patient compliant with Humira Summary of Product Characteristics
- Patient compliant with Belgian reimbursement criteria of Humira in plaque psoriasis
- Patient has signed informed consent
Exclusion
- Patients having any of the contraindications mentioned in the Summary of Product Characteristics Humira
- Patients not willing to sign informed consent
Key Trial Info
Start Date :
May 1 2010
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 1 2015
Estimated Enrollment :
191 Patients enrolled
Trial Details
Trial ID
NCT01169987
Start Date
May 1 2010
End Date
March 1 2015
Last Update
July 13 2016
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.